CA2873653A1 - Process for making hydroxylated cyclopentylpyrimidine compounds - Google Patents

Process for making hydroxylated cyclopentylpyrimidine compounds Download PDF

Info

Publication number
CA2873653A1
CA2873653A1 CA2873653A CA2873653A CA2873653A1 CA 2873653 A1 CA2873653 A1 CA 2873653A1 CA 2873653 A CA2873653 A CA 2873653A CA 2873653 A CA2873653 A CA 2873653A CA 2873653 A1 CA2873653 A1 CA 2873653A1
Authority
CA
Canada
Prior art keywords
formula
compound
salt
methyl
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873653A
Other languages
English (en)
French (fr)
Inventor
Jonathan W. LANE
Travis Remarchuk
Sagar Shakya
Keith L. Spencer
Peter J. Stengel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Array Biopharma Inc
Original Assignee
Genentech Inc
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Array Biopharma Inc filed Critical Genentech Inc
Publication of CA2873653A1 publication Critical patent/CA2873653A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2873653A 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds Abandoned CA2873653A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648421P 2012-05-17 2012-05-17
US61/648,421 2012-05-17
US201361785281P 2013-03-14 2013-03-14
US61/785,281 2013-03-14
PCT/US2013/041624 WO2013173736A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (1)

Publication Number Publication Date
CA2873653A1 true CA2873653A1 (en) 2013-11-21

Family

ID=48534507

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873653A Abandoned CA2873653A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Country Status (18)

Country Link
US (1) US9309204B2 (enExample)
EP (1) EP2861583B1 (enExample)
JP (1) JP6214636B2 (enExample)
KR (1) KR20150020211A (enExample)
CN (1) CN104487430B (enExample)
AU (1) AU2013262568B2 (enExample)
BR (1) BR112014028570A2 (enExample)
CA (1) CA2873653A1 (enExample)
DK (1) DK2861583T3 (enExample)
ES (1) ES2588878T3 (enExample)
IL (1) IL235714A0 (enExample)
MA (1) MA37649B1 (enExample)
MX (1) MX2014013865A (enExample)
PL (1) PL2861583T3 (enExample)
RU (1) RU2014151017A (enExample)
SG (1) SG11201407613RA (enExample)
SI (1) SI2861583T1 (enExample)
WO (1) WO2013173736A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2858989T (lt) 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
BR112014028585B1 (pt) 2012-05-17 2020-12-22 Genentech , Inc processo para fabricação de aminoácidos, e seus intermediários
CN112898210B (zh) 2013-11-15 2025-02-21 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
KR102284944B1 (ko) * 2013-11-27 2021-08-03 선샤인 레이크 파르마 컴퍼니 리미티드 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법
PL3197875T3 (pl) * 2014-09-26 2020-03-31 F. Hoffmann-La Roche Ag Sposoby wytwarzania związków (cyklopentylo[d]pirymidyn-4-ylo)piperazynowych
CN120887837A (zh) 2020-06-16 2025-11-04 豪夫迈·罗氏有限公司 用于制备羟基化环戊基嘧啶化合物的方法
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015684A1 (en) 1993-12-12 1995-06-15 Agrogene, Ltd. A novel method to protect plants from fungal infection
WO1998044797A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1281604C (zh) * 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
JP5157576B2 (ja) 2007-05-14 2013-03-06 住友化学株式会社 光学活性2−アルキル−1,1,3−トリアルコキシカルボニルプロパンの製造方法
MX2009014013A (es) * 2007-07-05 2010-01-28 Array Biopharma Inc Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
US8835434B2 (en) * 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
BR112012011328A2 (pt) 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
BR112014028585B1 (pt) 2012-05-17 2020-12-22 Genentech , Inc processo para fabricação de aminoácidos, e seus intermediários
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES

Also Published As

Publication number Publication date
JP6214636B2 (ja) 2017-10-18
EP2861583B1 (en) 2016-06-29
PL2861583T3 (pl) 2016-12-30
SI2861583T1 (sl) 2016-10-28
AU2013262568B2 (en) 2017-08-31
EP2861583A1 (en) 2015-04-22
MX2014013865A (es) 2015-05-07
ES2588878T3 (es) 2016-11-07
RU2014151017A (ru) 2016-07-10
AU2013262568A1 (en) 2015-01-22
US9309204B2 (en) 2016-04-12
BR112014028570A2 (pt) 2018-04-24
IL235714A0 (en) 2015-02-01
US20150099881A1 (en) 2015-04-09
MA37649B1 (fr) 2017-03-31
KR20150020211A (ko) 2015-02-25
DK2861583T3 (en) 2016-10-03
WO2013173736A1 (en) 2013-11-21
SG11201407613RA (en) 2015-01-29
JP2015518837A (ja) 2015-07-06
CN104487430A (zh) 2015-04-01
HK1208673A1 (en) 2016-03-11
MA37649A1 (fr) 2016-06-30
CN104487430B (zh) 2016-08-24

Similar Documents

Publication Publication Date Title
DK2861583T3 (en) METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER
CA2873661C (en) Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
CA2873654C (en) Process for making hydroxylated cyclopentylpyrimidine compounds
US9278917B2 (en) Process for making amino acid compounds
AU2019253849B2 (en) Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208673B (en) Process for making hydroxylated cyclopentylpyrimidine compounds
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180517